Lung Cancer Screening With Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial
Overview
Pulmonary Medicine
Authors
Affiliations
Introduction: Patients with a prior history of cancer (PHC) are at increased risk of second primary malignancy, of which lung cancer is the most common. We compared the performance metrics of positive screening rates and cancer detection rates (CDRs) among those with versus without PHC.
Methods: We conducted a secondary analysis of 26,366 National Lung Screening Trial participants screened with low dose computed tomography between August 2002 and September 2007. We evaluated absolute rates and age-adjusted relative risks (RRs) of positive screening rates on the basis of retrospective Lung CT Screening Reporting & Data System (Lung-RADS) application, invasive diagnostic procedure rate, complication rate, and CDR in those with versus without PHC using a binary logistic regression model using Firth's penalized likelihood. We also compared cancer type, stage, and treatment in those with versus without PHC.
Results: A total of 4.1% (n = 1071) of patients had PHC. Age-adjusted rates of positive findings were similar in those with versus without PHC (Baseline: PHC = 13.7% versus no PHC = 13.3%, RR [95% confidence interval (CI)]: 1.04 [0.88-1.24]; Subsequent: PHC = 5.6% versus no PHC = 5.5%, RR [95% CI]: 1.02 [0.84-1.23]). Age-adjusted CDRs were higher in those with versus without PHC on baseline (PHC=1.9% versus no PHC = 0.8%, RR [95% CI]: 2.51 [1.67-3.81]) but not on subsequent screenings (PHC = 0.6% versus no PHC = 0.4%, RR [95% CI]: 1.37 [0.99-1.93]). There were no differences in cancer stage, type, or treatment by PHC status.
Conclusions: Patients with PHC may benefit from lung cancer screening, and with their providers, should be made aware of the possibility of higher cancer detection, invasive procedures, and complication rates on baseline lung cancer screening, but not on subsequent low dose computed tomography screening examinations.
Alshammari A Biomedicines. 2023; 11(5).
PMID: 37239025 PMC: 10216652. DOI: 10.3390/biomedicines11051354.
Deep learning-based detection algorithm for brain metastases on black blood imaging.
Oh J, Lee K, Kim H, Yoon J, Kim E Sci Rep. 2022; 12(1):19503.
PMID: 36376364 PMC: 9663732. DOI: 10.1038/s41598-022-23687-8.
Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.
Bonney A, Malouf R, Marchal C, Manners D, Fong K, Marshall H Cochrane Database Syst Rev. 2022; 8:CD013829.
PMID: 35921047 PMC: 9347663. DOI: 10.1002/14651858.CD013829.pub2.
Subsequent Primary Cancer Risk Among 5-Year Survivors of Adolescent and Young Adult Cancers.
Sung H, Siegel R, Hyun N, Miller K, Yabroff K, Jemal A J Natl Cancer Inst. 2022; 114(8):1095-1108.
PMID: 35511931 PMC: 9360462. DOI: 10.1093/jnci/djac091.
European lung cancer screening: valuable trial evidence for optimal practice implementation.
Silva M, Milanese G, Ledda R, Nayak S, Pastorino U, Sverzellati N Br J Radiol. 2022; 95(1133):20200260.
PMID: 34995141 PMC: 10993986. DOI: 10.1259/bjr.20200260.